BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virology 2015; 4(2): 105-112 [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105]
URL: https://www.wjgnet.com/2220-3249/full/v4/i2/105.htm
Number Citing Articles
1
Mary-Ann Davies, Diana Gibb, Anna Turkova. Survival of HIV-1 vertically infected childrenCurrent Opinion in HIV and AIDS 2016; 11(5): 455 doi: 10.1097/COH.0000000000000303
2
Mary Kagujje, Winnie Mwanza, Paul Somwe, Lophina Chilukutu, Jacob Creswell, Monde Muyoyeta. Sensitivity and specificity of CRP and symptom screening as tuberculosis screening tools among HIV-positive and negative outpatients at a primary healthcare facility in Lusaka, Zambia: a prospective cross-sectional studyBMJ Open 2023; 13(4): e061907 doi: 10.1136/bmjopen-2022-061907
3
Camila Melo Picone, Angela Carvalho Freitas, Eliana B. Gutierrez, Vivian Iida Avelino-Silva. Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV: a retrospective cohort study in Sao Paulo, BrazilRevista do Instituto de Medicina Tropical de São Paulo 2020; 62 doi: 10.1590/s1678-9946202062008
4
W. Chris Buck, Hanh Nguyen, Mariana Siapka, Lopa Basu, Jessica Greenberg Cowan, Maria Inês De Deus, Megan Gleason, Ferreira Ferreira, Carla Xavier, Benedita Jose, Criménia Muthemba, Beatriz Simione, Peter Kerndt. Integrated TB and HIV care for Mozambican children: temporal trends, site-level determinants of performance, and recommendations for improved TB preventive treatmentAIDS Research and Therapy 2021; 18(1) doi: 10.1186/s12981-020-00325-9
5
David W. Dowdy, Jonathan E. Golub. Handbook of Tuberculosis2017; : 119 doi: 10.1007/978-3-319-26273-4_5
6
Ellen Brooks-Pollock, Karen R Jacobson. Rethinking tuberculosis control by targeting previously treated individualsThe Lancet Global Health 2018; 6(4): e361 doi: 10.1016/S2214-109X(18)30068-8
7
Tinashe Mudzviti, Tinei Shamu, Cleophas Chimbetete, Tilda Munengerwa, Sandra Bote, Margaret Pascoe. Tolerability of Isoniazid Preventive Therapy in an HIV-Infected Cohort of Paediatric and Adolescent Patients on Antiretroviral Therapy from a Resource-Limited Setting: A Retrospective Cohort StudyDrugs - Real World Outcomes 2019; 6(1): 37 doi: 10.1007/s40801-019-0147-3
8
Mary Kagujje, Muhau L. Mubiana, Eugenia Mwamba, Monde Muyoyeta. Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessonsBMC Public Health 2019; 19(1) doi: 10.1186/s12889-019-7652-x
9
Mulugeta Russom, Daniel Y. B. Jeannetot, Araia Berhane, Henok G. Woldu, Bruno H. Stricker, Katia M. C. Verhamme. Liver Injury Following Isoniazid Preventive Therapy in HIV Patients Attending Halibet National Referral Hospital, Eritrea: A Prospective Cohort StudyDrugs - Real World Outcomes 2023; 10(3): 383 doi: 10.1007/s40801-023-00375-1